Table 1.
Clinicopathological variables for patients.
| Characteristic | Training cohort | Validaton cohort | Total | P |
|---|---|---|---|---|
| N= | N= | N= | ||
| No. (%) | No. (%) | No. (%) | ||
| Age | 0.990 | |||
| <13 | 132 (27.6%) | 38 (27.7%) | 170 (27.6%) | |
| 13–28 | 279 (58.2%) | 79 (57.7%) | 358 (58.1%) | |
| >28 | 68 (14.2%) | 20 (14.6%) | 88 (14.3%) | |
| Gender | 0.714 | |||
| Male | 303 (64.0%) | 89 (65.0%) | 392 (63.6%) | |
| Female | 176 (36.7%) | 48 (35.0%) | 224 (36.4%) | |
| Ethnicity | 0.781 | |||
| Spanish-Hispanic-Latino | 106 (22.1%) | 52 (38.0%) | 158 (25.6%) | |
| Non-Spanish-Hispanic-Latino | 373 (77.9%) | 85 (62.0%) | 458 (74.4%) | |
| Race | 0.901 | |||
| White | 432 (90.2%) | 122 (89.1%) | 554 (89.9%) | |
| Black | 14 (2.9%) | 4 (2.9%) | 18 (2.9%) | |
| other | 33 (6.9%) | 11 (8.0%) | 44 (7.1%) | |
| Stage | 0.083 | |||
| Localized | 143 (29.9%) | 29 (21.2%) | 172 (27.9%) | |
| Regiinal | 192 (40.1%) | 56 (40.9%) | 248 (40.3%) | |
| Distant | 144 (30.1%) | 52 (38.0%) | 192 (31.8%) | |
| Tumorsite | 0.721 | |||
| Axial | 160 (33.4%) | 48 (35.0%) | 294 (33.8%) | |
| Appendix | 319 (66.6%) | 89 (65.0%) | 322 (66.2%) | |
| Tumorsize | 0.687 | |||
| <71 | 198 (41.3%) | 51 (37.2%) | 249 (40.4%) | |
| 71–115 | 159 (33.2%) | 49 (35.8%) | 208 (33.8%) | |
| >115 | 122 (25.5%) | 37 (27.0%) | 159 (25.8%) | |
| Surgery | 0.798 | |||
| Yes | 309 (64.5%) | 90 (65.7%) | 399 (64.8%) | |
| No | 170 (35.5%) | 47 (34.3%) | 217 (35.2%) | |
| Radiotherapy | 0.481 | |||
| Yes | 122 (25.5%) | 39 (28.5%) | 161 (26.1%) | |
| No | 357 (74.5%) | 98 (71.5%) | 455 (73.9%) | |
| Chemotherapy | 0.999 | |||
| Yes | 465 (97.1%) | 133 (97.1%) | 598 (97.1%) | |
| No | 14 (2.9%) | 4 (2.9%) | 18 (2.9%) |
Other, American Indian/AK Native, Asian/Pacifc Islander; NSHL, Nonspanish-Hispanic-Latino.